Jacobson & Schmitt Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Jacobson & Schmitt Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,000	Closed	-$208K	–	62
2023 Q1	$208K	Hold	3,000	–	–	0.06%	63
2022 Q4	$213K	Hold	3,000	–	–	0.07%	53
2022 Q3	$213K	Hold	3,000	–	–	0.07%	53
2022 Q2	$231K	Hold	3,000	–	–	0.07%	48
2022 Q1	$219K	Buy	+3,000	New	+$201K	0.06%	59

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Jacobson & Schmitt Advisors's BMY Position: Q2 2023 in Review

Jacobson & Schmitt Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2023, closing a stake of 3,000 shares — an estimated $208K sold.

Jacobson & Schmitt Advisors first reported a position in BMY in Q1 2022 and held it in 5 quarters. The position peaked at $231K in Q2 2022. 2,480 funds tracked by Wall St. Rank hold BMY as of Q2 2023.

Jacobson & Schmitt Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2023 after selling out during the quarter.
Jacobson & Schmitt Advisors sold 3,000 Bristol-Myers Squibb shares in Q2 2023, an estimated $208K.
Jacobson & Schmitt Advisors first reported a position in Bristol-Myers Squibb in Q1 2022 and held it in 5 quarters.
Jacobson & Schmitt Advisors's Bristol-Myers Squibb position peaked at $231K in Q2 2022.
2,480 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.

Based on Jacobson & Schmitt Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.